Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217904 | 0.85 | MTNR1A (0.37) | MTNR1AKMT2APPARAPTGS1AKR1C3 | |
| SCHEMBL220495 | 0.83 | PPARA (0.41) | SMN1; SMN2MAPTKMT2AL3MBTL1PPARA | |
| SCHEMBL220497 | 0.83 | PPARA (0.41) | SMN1; SMN2MAPTKMT2AL3MBTL1PPARA | |
| SCHEMBL1396028 | 0.83 | KDM4E (0.40) | L3MBTL1PPARAPTGS1AKR1C3AKR1C2 | |
| SCHEMBL27816060 | 0.83 | KDM4E (0.40) | L3MBTL1PPARAPTGS1AKR1C3AKR1C2 | |
| SCHEMBL218755 | 0.80 | AKR1C3 (0.36) | KMT2AMEN1L3MBTL1PPARAPTGS1 | |
| SCHEMBL218757 | 0.80 | AKR1C3 (0.36) | KMT2AMEN1L3MBTL1PPARAPTGS1 | |
| SCHEMBL5149460 | 0.80 | PTGS1 (0.44) | MAPTMTNR1AKMT2AMEN1PTGS1 | |
| SCHEMBL219508 | 0.79 | AKR1C3 (0.35) | KMT2AMEN1L3MBTL1PPARAPTGS1 | |
| SCHEMBL220239 | 0.79 | PTGS2 (0.36) | L3MBTL1PTGS1AKR1C3AKR1C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304409-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8088762-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20110098253-A1 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use | NICOX S.A. (IT) | 2011-04-28 | — | — | US | disclosed |
| US-7883714-B2 | (2R)-2,3-bis(nitrooxy)propyl(2S)-2(6-methoxy(2-naphthyl)propanoate, used for treating inflammation, pain and fever; gastrointestinal disorders; wound healing agents; preventing gastrointestinal, renal and/or respiratory toxicities; side effect reduction; kits | NICOX S.A. (FR) | 2011-02-08 | — | — | US | disclosed |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100093671-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-04-15 | — | — | US | disclosed |
| US-20100093708-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-04-15 | — | — | US | disclosed |
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093708-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | SMN1; SMN2 2338/4885MAPT 3779/4885MTNR1A 409/4885 |
| US-20110098253-A1 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use | NOS2, NOS1, NOS3 | SMN1; SMN2 2499/4885MAPT 3591/4885MTNR1A 208/4885 |
| US-20100093671-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | SMN1; SMN2 2338/4885MAPT 3779/4885MTNR1A 409/4885 |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | SMN1; SMN2 2338/4885MAPT 3779/4885MTNR1A 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.